Tharimmune
Bridgewater, US · Delaware corporation · 1 known investors
Find your way into Tharimmune
Sign up to see every warm intro you have to Tharimmune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tharimmune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
TH
Thomas HessChief Financial Officer
SA
Sireesh AppajosyulaChief Operating OfficerSireesh Appajosyula is Chief Operating Officer at Tharimmune, a biotechnology company developing therapies for autoimmune and oncologic diseases.
Board
LA
Lynne A/ BuiBoard director
SP
Sanam ParikhBoard director
LM
Leonard MazurBoard director
KA
Kelly AndersonBoard director
Investors · 1
GravitasreportedChapel Hill
How we know: press coverage · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.6M disclosed across 5 rounds · 2024–2025
▶$1.2MraisedApr 2026 · 6 investors · BiotechnologyRule 506(b)
▶$1.2MraisedApr 2026 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vincent LoPrioreDirector
- Clay KahlerDirector
- Jill SommersDirector
- Angela RadkowskiExecutive Officer
- Mark ToomeyExecutive Officer
- Sireesh AppajosyulaDirector
- Jacob AsburyExecutive Officer
- Gary StetzDirector
- William WileyDirector
- Mark WendlandExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- Sales commissions
- $85.8K
- Placement agents
- President Street Global LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedApr 2026 · 13 investors · BiotechnologyRule 506(b)
▶$1.7MraisedApr 2026 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark WendlandExecutive Officer, Director
- Angela RadkowskiExecutive Officer
- Clay KahlerDirector
- Sireesh AppajosyulaDirector
- Jill SommersDirector
- Gary StetzDirector
- Mark ToomeyExecutive Officer
- Vincent LoPrioreDirector
- William WileyDirector
- Jacob AsburyExecutive Officer
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- Sales commissions
- $121.8K
- Placement agents
- President Street Global LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedJul 2025 · 30 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJul 2025 · 30 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Clay KahlerDirector
- James Gordon LiddyDirector
- Sireesh AppajosyulaExecutive Officer, Director
- Gary StetzDirector
- Sanam ParikhDirector
- Vincent LoPrioreExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Sales commissions
- $175K
- Placement agents
- President Street Global, LLC
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedDec 2024 · 7 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2024 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HessExecutive Officer
- Sireesh AppajosyulaExecutive Officer, Director
- Lynne A/ BuiDirector
- Sanam ParikhDirector
- Leonard MazurDirector
- Kelly AndersonDirector
- Randy MilbyExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $121.2K
- Placement agents
- President Street Global, LLC
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJun 2024 · 5 investors · BiotechnologyRule 506(b)
▶$2.1MraisedJun 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy MilbyExecutive Officer, Director
- Kelly AndersonDirector
- Leonard MazurDirector
- Sireesh AppajosyulaExecutive Officer, Director
- Thomas HessExecutive Officer
- Lynne A BuiDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Sales commissions
- $125K
- Placement agents
- President Street Global, LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Tharimmune's investors?
- Tharimmune's investors include Gravitas.
- How much funding has Tharimmune raised?
- Tharimmune has disclosed $9.6M raised across 5 rounds.
- Where is Tharimmune headquartered?
- Tharimmune is headquartered in Bridgewater, US.